A phase II study of Trastuzumab with S-1 plus Oxaliplatin for HER2 positive advanced gastric cancer
- Conditions
- gastric cancer
- Registration Number
- JPRN-UMIN000017602
- Lead Sponsor
- Cancer Institute Hospital Japanese Foundation For Cancer Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 75
Not provided
1) could not administrate S-1,Oxaliplatin,and Trastuzumab 2)pregnant and/or nursing women or men who wish to have children in future 3)with actuve infectious disease 4)HBs antigen positive 5)with a histroy or current symptoms of heart failure, uncontrollable arrhythmia,angina pectoris,valvular disease,and uncontrollable hypertension 6)with interstitial pneumonia, pulmonary fibrosis, heart hailure, renal failure, hepatic failure, uncontrollable diabetes mellitus 7)with dyspnea at rest 8)with active bleeding from gastric cancer/ulcer 9)with severe diarrhea(over 4 times a day or watery diarrhea) 10)with severe sensory neuropathy 11)with active double cancers excluding carcinoma in situ and/or prior curative cancer with relapse free for more than 5 years 12)under meditation of flucytosine, phenytoin,or warfarin 13) under continuous meditation of steroids 14)judged to be unfit to participate in this study by investigater
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response Rate
- Secondary Outcome Measures
Name Time Method Progression free survival,Overall survival, Safety